Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARZ-005
- Development stage
- Preclinical
- Lead developer
- Artizan Biosciences
- Modality
- Small Molecules
01
Overview
ARZ-005 is a **preclinical small-molecule drug candidate** being developed by **Artizan Biosciences** for **inflammatory bowel disease**. Publicly available sources identify it as an internally developed investigational program in Artizan's pipeline, but do not provide a validated disclosure of its precise molecular target, mechanism of action, formulation details, or route of administration. Based on currently accessible information, it should be characterized as an early-stage, non-approved pharmaceutical candidate for immune and gastrointestinal disorders, with inflammatory bowel disease as the most clearly associated indication.
Beyond the preview
Go deeper on ARZ-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARZ-005.